Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glial Activity Load on PET Reveals Persistent "Smoldering" Inflammation in MS Despite Disease-Modifying Treatment: 18 F-PBR06 Study.
Singhal T, Cicero S, Rissanen E, Ficke J, Kukreja P, Vaquerano S, Glanz B, Dubey S, Sticka W, Seaver K, Kijewski M, Callen AM, Chu R, Carter K, Silbersweig D, Chitnis T, Bakshi R, Weiner HL. Singhal T, et al. Clin Nucl Med. 2024 Jun 1;49(6):491-499. doi: 10.1097/RLU.0000000000005201. Epub 2024 Apr 17. Clin Nucl Med. 2024. PMID: 38630948
A study of referral bias in NMOSD and MOGAD cohorts.
Leal Rato M, Chen B, Francis A, Messina S, Miron M, Sharawakanda Y, O'Sullivan E, Cooper S, Fisniku L, Halfpenny C, Martin R, Hobart J, Rashid W, Hemingway C, Williams V, Hacohen Y, Dobson R, Ramdas S, Leite MI, Palace J, Geraldes R. Leal Rato M, et al. Mult Scler Relat Disord. 2024 May;85:105553. doi: 10.1016/j.msard.2024.105553. Epub 2024 Mar 14. Mult Scler Relat Disord. 2024. PMID: 38552551 Free article.
Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis, the ProVal-MS study.
Bayas A, Mansmann U, Ön BI, Hoffmann VS, Berthele A, Mühlau M, Kowarik MC, Krumbholz M, Senel M, Steuerwald V, Naumann M, Hartberger J, Kerschensteiner M, Oswald E, Ruschil C, Ziemann U, Tumani H, Vardakas I, Albashiti F, Kramer F, Soto-Rey I, Spengler H, Mayer G, Kestler HA, Kohlbacher O, Hagedorn M, Boeker M, Kuhn K, Buchka S, Kohlmayer F, Kirschke JS, Behrens L, Zimmermann H, Bender B, Sollmann N, Havla J, Hemmer B; ProVal-MS study group. Bayas A, et al. Neurol Res Pract. 2024 Mar 7;6(1):15. doi: 10.1186/s42466-024-00310-x. Neurol Res Pract. 2024. PMID: 38449051 Free PMC article.
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.
Liyanage G, Trewin BP, Lopez JA, Andersen J, Tea F, Merheb V, Nguyen K, Lee FXZ, Fabis-Pedrini MJ, Zou A, Buckland A, Fok A, Barnett MH, Reddel SW, Marignier R, El Hajj A, Monif M, van der Walt A, Lechner-Scott J, Kermode AG, Kalincik T, Broadley SA, Dale RC, Ramanathan S, Brilot F; on behalf the Australasian MOGAD Study Group. Liyanage G, et al. J Neurol Neurosurg Psychiatry. 2024 Jan 30:jnnp-2023-332851. doi: 10.1136/jnnp-2023-332851. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 38290838 Free article.
Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
Abdelhak A, Antweiler K, Kowarik MC, Senel M, Havla J, Zettl UK, Kleiter I, Skripuletz T, Haarmann A, Stahmann A, Huss A, Gingele S, Krumbholz M, Benkert P, Kuhle J, Friede T, Ludolph AC, Ziemann U, Kümpfel T, Tumani H. Abdelhak A, et al. Ann Clin Transl Neurol. 2024 Feb;11(2):477-485. doi: 10.1002/acn3.51969. Epub 2023 Dec 19. Ann Clin Transl Neurol. 2024. PMID: 38111972 Free PMC article.
137 results